IQVIA (NYSE:IQV) Cut to “Hold” at StockNews.com

StockNews.com downgraded shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research report released on Thursday morning.

A number of other analysts also recently commented on the company. The Goldman Sachs Group dropped their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. BTIG Research cut their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Friday, November 1st. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Redburn Atlantic started coverage on shares of IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Trading Down 0.3 %

NYSE IQV opened at $200.84 on Thursday. The company has a market cap of $36.45 billion, a P/E ratio of 26.36, a P/E/G ratio of 2.07 and a beta of 1.51. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a 50-day moving average of $218.67 and a 200-day moving average of $226.11.

Hedge Funds Weigh In On IQVIA

A number of institutional investors have recently made changes to their positions in the business. PGGM Investments grew its position in shares of IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after acquiring an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. boosted its position in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the period. Raymond James & Associates increased its holdings in shares of IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after purchasing an additional 5,417 shares during the period. Versor Investments LP bought a new stake in shares of IQVIA during the 3rd quarter worth about $1,328,000. Finally, Gradient Investments LLC raised its holdings in IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after purchasing an additional 6,134 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.